Biogen

Corporate brand

Biogen is a U.S.-based biotechnology company focused on medicines for neurological, neurodegenerative, neuromuscular, immunological, and rare diseases.

Last updated October 14, 2026

AI crawler reads

No AI crawler has read this profile since Oct 28, 2026.

Overview

Biogen is an American biotechnology and biopharmaceutical company headquartered in Cambridge, Massachusetts. Founded in 1978 in Geneva as Biotechnology Geneva, the company was established by a group of internationally recognized molecular biologists, including Nobel laureates Walter Gilbert and Phillip Allen Sharp, together with Kenneth Murray, Heinz Schaller, and Charles Weissmann. Biogen was created during the formative period of modern biotechnology, when recombinant-DNA science was beginning to move from academic laboratories into commercial medicine. The company initially built value through scientific partnerships, licensing, and the development of biologic medicines. Early research and licensing work contributed to technologies used in interferon and hepatitis B vaccination. Biogen relocated much of its operational base to the United States in the early 1980s and developed a major presence in Cambridge's Kendall Square biotechnology community. It later established substantial research, pharmaceutical-operations, and manufacturing capabilities in North Carolina's Research Triangle Park and other international locations. A major turning point came with the 2003 merger between Biogen and IDEC Pharmaceuticals, a San Diego biotechnology company known particularly for antibody-based cancer and immunology medicines. The combined company adopted the name Biogen Idec and gained a broader portfolio spanning neurology, oncology, and immunology. IDEC's contribution included Rituxan, developed with Genentech and Roche, while Biogen brought its established multiple-sclerosis franchise, led by Avonex. In 2015, the company shortened its name to Biogen, restoring the original corporate identity while emphasizing its focus on high-unmet-need diseases. Biogen became especially associated with multiple sclerosis through Avonex, Tysabri, Tecfidera, Plegridy, and Vumerity. These therapies helped make MS the company's commercial foundation for many years. The company subsequently diversified into neuromuscular disease with Spinraza, the first approved treatment for spinal muscular atrophy, and into rare disease with Skyclarys for Friedreich's ataxia. It also developed Qalsody, an antisense medicine for a genetically defined form of amyotrophic lateral sclerosis, and expanded its portfolio through biosimilars, partnerships, and acquisitions. Biogen has also pursued Alzheimer's disease through its collaboration with Eisai. Aduhelm, an amyloid-targeting antibody developed with Eisai, received accelerated approval from the U.S. Food and Drug Administration in 2021. The approval generated substantial debate over the interpretation of clinical evidence, the use of the accelerated-approval pathway, reimbursement, and the relationship between amyloid reduction and clinical benefit. Biogen and Eisai later commercialized Leqembi, which received traditional U.S. approval in 2023 and became a more important part of the companies' Alzheimer's strategy. Biogen has also partnered with Sage Therapeutics on Zurzuvae, an oral treatment for postpartum depression. In the 2020s, Biogen sought to reduce dependence on mature MS products and create a broader growth portfolio in rare disease, immunology, neurology, and specialty medicine. The company acquired Human Immunology Biosciences in 2024, adding felzartamab and a kidney-disease development platform. In 2026, Biogen announced an agreement to acquire Apellis Pharmaceuticals, subject to customary closing conditions, to add the commercial products Empaveli and Syfovre and expand into complement-mediated immunology, nephrology, and retinal disease. Biogen's products are distributed in more than 100 countries through affiliates and commercial partners. Its business combines internal discovery and development, manufacturing of biologics and oligonucleotide medicines, strategic collaborations, licensing, and commercialization of specialty pharmaceuticals. The company continues to present itself as a science-led organization centered on neurological and rare diseases while increasingly investing in immunology, kidney disease, retinal disease, and other areas where it believes specialized biology can support differentiated therapies.

History

Biogen was founded in 1978 in Geneva under the name Biotechnology Geneva by a group of molecular biologists who sought to commercialize advances in recombinant DNA and molecular biology. The founding group included Kenneth Murray, Phillip Allen Sharp, Walter Gilbert, Heinz Schaller, and Charles Weissmann. Gilbert and Sharp later received Nobel Prizes for work related to nucleic-acid science and RNA splicing, reinforcing the company's early association with leading academic biology. During its first phase, Biogen operated primarily as a science and licensing company rather than as a fully integrated pharmaceutical manufacturer. It developed intellectual property and entered commercial relationships around interferon and hepatitis B technologies. In 1979, the company licensed alpha-interferon patent rights to Schering-Plough. In 1988, it licensed hepatitis B technology to SmithKline Beecham. These arrangements helped demonstrate how a biotechnology company could create value by combining academic discoveries, patent rights, and pharmaceutical partnerships. Biogen relocated much of its operating base to the United States in the early 1980s and established a long-term presence in Cambridge, Massachusetts. The company became part of the emerging Kendall Square biotechnology cluster, eventually combining corporate headquarters, research, and manufacturing activities in the region. It also developed production facilities in North Carolina's Research Triangle Park, where its manufacturing footprint later became one of the company's largest operational assets. The 1990s marked Biogen's transition from a technology-centered biotechnology company into a commercial medicines business. Avonex, an interferon beta-1a product for relapsing forms of multiple sclerosis, received U.S. approval in 1996 and became the foundation of Biogen's long-term MS franchise. During the same period, IDEC Pharmaceuticals, founded in 1985 in San Diego, developed Rituxan with Genentech and Roche. Rituxan's approval in 1997 represented an important milestone for antibody-based cancer treatment and gave IDEC a strong position in oncology and immunology. Biogen and IDEC announced their merger in 2003 and completed the transaction on November 12 of that year. The combined company became Biogen Idec. Although the transaction was legally structured through IDEC's corporate entity, the resulting organization combined Biogen's neurology portfolio and scientific heritage with IDEC's antibody expertise and oncology operations. The merged company expanded globally and pursued medicines across neurology, immunology, oncology, and other specialty areas. The company strengthened its MS position during the 2000s. Tysabri was reintroduced in the United States in 2006 and launched in the European Union, while later approvals expanded its use. Biogen Idec also developed manufacturing and commercial operations in countries including Brazil, China, and India. In 2013, Tecfidera was approved in the United States for relapsing forms of multiple sclerosis and became one of the company's most commercially important products. Plegridy followed as a pegylated interferon option, and the fumarate franchise was later expanded with Vumerity. In 2015, Biogen Idec returned to the shorter Biogen name. The rebranding reflected the company's decision to emphasize its original identity and its concentration on neurology and diseases with substantial unmet need. Around the same period, the company made a major move into spinal muscular atrophy through a collaboration with Ionis Pharmaceuticals. Spinraza was approved in 2016 and became the first approved treatment for SMA, establishing Biogen as a major neuromuscular-disease company. Biogen's later history has included both successful launches and difficult development programs. The company partnered with Eisai on Alzheimer's disease research, ultimately leading to Aduhelm and Leqembi. Aduhelm received accelerated FDA approval in June 2021, but the decision provoked debate about the clinical evidence, the use of a surrogate endpoint, reimbursement, and the role of advisory-committee disagreement. The confirmatory program and commercial rollout subsequently struggled. Leqembi, also developed with Eisai, received accelerated approval in 2023 and later traditional approval, giving the partnership a more durable Alzheimer's platform. The company also expanded beyond MS through the acquisition of Nightstar Therapeutics in 2019, its collaboration with Sage Therapeutics on zuranolone, and its acquisition of Human Immunology Biosciences in 2024. These transactions and partnerships supported diversification into gene therapy, psychiatry, immunology, and kidney disease. Skyclarys, approved in 2023 for Friedreich's ataxia, and Qalsody, approved the same year for SOD1-associated ALS, reinforced Biogen's rare-neurology strategy. In the mid-2020s, Biogen began emphasizing a broader growth portfolio spanning neurology, rare disease, immunology, nephrology, retinal disease, and specialty medicines. It announced major investments in North Carolina manufacturing and plans for a new Cambridge headquarters. In 2026, it announced a proposed acquisition of Apellis Pharmaceuticals, intended to add Empaveli and Syfovre and expand Biogen's commercial and clinical presence in complement-mediated disease. Biogen remains an independent, publicly traded biotechnology company with products supplied to more than 100 countries and a business model built around internal research, strategic partnerships, licensing, acquisitions, and specialized manufacturing.

2026
Proposed Apellis acquisition
[10]Biogen and Apellis transaction announcementinvestors.biogen.com
Biogen announces an agreement to acquire Apellis Pharmaceuticals, subject to closing conditions, to expand its immunology, nephrology, rare-disease, and retinal-disease portfolio.
2025
North Carolina manufacturing investment
[17]North Carolina manufacturing investmentbiogen.com
Biogen announces a further $2 billion investment in Research Triangle Park manufacturing and technology capabilities.
2024
Human Immunology Biosciences acquisition
[16]Human Immunology Biosciences acquisitioninvestors.biogen.com
Biogen completes its acquisition of HI-Bio, adding an immunology and nephrology platform centered on felzartamab.
2023
Qalsody and Skyclarys are approved
[15]Qalsody and Skyclarys are approvedfda.gov
The FDA approves Qalsody for SOD1-associated ALS and Skyclarys for Friedreich's ataxia, broadening Biogen's rare-neurology portfolio.
2023
Leqembi receives traditional approval
[9]FDA Leqembi traditional approvalfda.gov
The FDA converts Leqembi's accelerated approval to traditional approval after confirmatory clinical evidence supported clinical benefit.
2021
Aduhelm receives accelerated approval
[8]FDA Aduhelm accelerated approvalfda.gov
The FDA grants accelerated approval to Aduhelm, the Biogen-Eisai Alzheimer's disease antibody, based on its effect on amyloid plaques.
2019
Biogen acquires Nightstar Therapeutics
[14]Biogen acquires Nightstar Therapeuticsinvestors.biogen.com
Biogen acquires Nightstar to expand its gene-therapy capabilities and rare-disease pipeline.
2016
Spinraza receives approval
[13]Spinraza receives approvalfda.gov
Spinraza becomes the first FDA-approved treatment for spinal muscular atrophy, establishing Biogen as a major neuromuscular-disease company.
2015
Biogen Idec becomes Biogen
[6]Biogen Idec becomes Biogeninvestors.biogen.com
The company changes its corporate name from Biogen Idec to Biogen and introduces a new identity centered on science and high-unmet-need diseases.
2013
Tecfidera receives U.S. approval
[12]Tecfidera receives U.S. approvalfda.gov
The FDA approves Tecfidera for relapsing forms of multiple sclerosis, adding an important oral therapy to Biogen's MS portfolio.
2006
Tysabri is reintroduced
[5]Biogen historical milestonesinvestors.biogen.com
Tysabri is reintroduced in the United States and launched in the European Union for relapsing forms of multiple sclerosis.
2003
Biogen and IDEC merge
[11]Biogen and IDEC mergeinvestors.biogen.com
The companies complete their merger and form Biogen Idec, combining major neurology, oncology, and immunology capabilities.
1997
Rituxan receives U.S. approval
[5]Biogen historical milestonesinvestors.biogen.com
IDEC's Rituxan, developed with Genentech and Roche, is approved for certain B-cell non-Hodgkin lymphomas and becomes a landmark antibody medicine.
1996
Avonex receives U.S. approval
[5]Biogen historical milestonesinvestors.biogen.com
The FDA approves Avonex for relapsing forms of multiple sclerosis, creating the foundation of Biogen's commercial MS franchise.
1988
Hepatitis B technology licensed
[5]Biogen historical milestonesinvestors.biogen.com
Biogen licenses hepatitis B technology to SmithKline Beecham, contributing to later vaccine products marketed by major pharmaceutical companies.
1979
Alpha-interferon patent licensing
[5]Biogen historical milestonesinvestors.biogen.com
Biogen grants worldwide rights to certain alpha-interferon patents to Schering-Plough, establishing an early commercial licensing relationship.
1978
Biotechnology Geneva is founded
[1]Biogen company overviewbiogen.com
Biogen is founded in Geneva by a group of molecular biologists including Kenneth Murray, Phillip Sharp, Walter Gilbert, Heinz Schaller, and Charles Weissmann.

Products and positioning

A specialist global biotechnology company positioned around innovative treatments for neurological, neurodegenerative, neuromuscular, immunological, and rare diseases, supported by biologics, antisense medicines, biosimilars, strategic partnerships, and specialty pharmaceuticals.

Multiple sclerosis biologic · 1996
Avonex
Avonex is an interferon beta-1a medicine for relapsing forms of multiple sclerosis. Approved in the United States in 1996, it was Biogen's first major commercial product and became a central part of the company's long-term MS franchise. The product helped establish Biogen as a specialist neurology company and supported later development and commercialization of additional MS therapies.
Multiple sclerosis and inflammatory disease biologic · 2004
Tysabri
Tysabri is natalizumab, a monoclonal antibody used for highly active relapsing multiple sclerosis and certain inflammatory bowel-disease indications. It is administered under risk-management requirements because of the potential for progressive multifocal leukoencephalopathy. Tysabri became one of Biogen's most important high-efficacy specialty medicines after its U.S. reintroduction in 2006.
Multiple sclerosis small molecule · 2013
Tecfidera
Tecfidera is an oral dimethyl fumarate treatment for relapsing forms of multiple sclerosis. Its convenient oral formulation and strong commercial uptake made it one of Biogen's most significant products after its U.S. approval in 2013. The product is part of Biogen's broader fumarate franchise, which also includes Vumerity and other regional formulations.
Multiple sclerosis small molecule · 2019
Vumerity
Vumerity is diroximel fumarate, an oral fumarate therapy developed for relapsing forms of multiple sclerosis. It was designed to provide the therapeutic benefits of the fumarate class with a potentially improved gastrointestinal tolerability profile compared with dimethyl fumarate. Vumerity extends Biogen's established MS franchise into a newer oral formulation.
Multiple sclerosis biologic · 2014
Plegridy
Plegridy is peginterferon beta-1a, a longer-acting interferon medicine for relapsing forms of multiple sclerosis. Pegylation allows less frequent administration than conventional interferon beta products. The medicine expanded Biogen's interferon portfolio and offered an alternative for patients and clinicians seeking a reduced injection schedule.
Neuromuscular antisense medicine · 2016
Spinraza
Spinraza is nusinersen, an antisense oligonucleotide for spinal muscular atrophy. It modifies SMN2 RNA splicing to increase production of functional survival motor neuron protein. Approved in 2016, it was the first FDA-approved treatment for SMA and became one of Biogen's defining rare-neuromuscular products.
Rare-disease small molecule · 2023
Skyclarys
Skyclarys is omaveloxolone, an oral medicine approved for Friedreich's ataxia, a progressive inherited neurodegenerative disorder. Its 2023 approval represented a major expansion of Biogen's rare-disease portfolio and gave the company a treatment positioned around a disease with few approved options.
ALS antisense medicine · 2023
Qalsody
Qalsody is tofersen, an antisense oligonucleotide for adults with amyotrophic lateral sclerosis associated with a mutation in the SOD1 gene. The medicine targets the genetic and molecular cause of a narrowly defined ALS subgroup. Its approval strengthened Biogen's position in genetically targeted neurology and antisense drug development.
Alzheimer's disease biologic · 2023
Leqembi
Leqembi is lecanemab, an anti-amyloid antibody developed jointly by Biogen and Eisai for early Alzheimer's disease. It is designed to remove aggregated amyloid-beta from the brain and became the partnership's principal Alzheimer's commercial product after traditional U.S. approval in 2023. The treatment requires infusion-based administration and monitoring for amyloid-related imaging abnormalities.
Alzheimer's disease biologic · 2021
Aduhelm
Aduhelm is aducanumab, an anti-amyloid antibody developed by Biogen and Eisai. The FDA granted accelerated approval in 2021 based on amyloid-plaque reduction, but the approval generated substantial debate over clinical benefit, trial interpretation, reimbursement, and regulatory process. Biogen and Eisai later discontinued the confirmatory and commercial program.
Postpartum-depression small molecule · 2023
Zurzuvae
Zurzuvae is zuranolone, an oral neuroactive steroid developed through Biogen's partnership with Sage Therapeutics. It was approved in 2023 as an oral treatment for postpartum depression and represented Biogen's move beyond traditional neurology into specialty psychiatry. The product is intended for a short treatment course rather than chronic daily use.
Biosimilar medicines · 2016
Biosimilars portfolio
Biogen has commercialized and partnered on biosimilar medicines, particularly in immunology and oncology. The portfolio has included products such as Benepali, Flixabi, and Imraldi in European markets. Biosimilars provide Biogen with a manufacturing and commercial business that complements its innovative-medicine portfolio and broadens access to established biologic therapies.
Dermatology small molecule · 1994
Fumaderm
Fumaderm is a fumarate-based medicine used in certain markets for severe plaque psoriasis. Biogen obtained the relevant business through its historical relationship with Fumapharm. The product was strategically important because its fumarate chemistry supported the later development of dimethyl fumarate medicines for multiple sclerosis.

Controversies

2022
Settlement concerning alleged improper physician payments
The U.S. Department of Justice announced that Biogen agreed to pay $900 million to resolve allegations that it caused false claims to be submitted to Medicare and Medicaid through improper payments to physicians. The resolution followed a whistleblower case under the False Claims Act and did not constitute an admission of liability by Biogen.
Source
2021
Aduhelm approval controversy
The FDA's accelerated approval of Aduhelm generated significant controversy because the decision relied on reduction of amyloid plaques as a surrogate endpoint while evidence of clinical benefit was disputed. The FDA advisory committee had voted overwhelmingly against approval, and subsequent debate involved trial results, regulatory standards, reimbursement, and post-approval evidence requirements.
Source

2026
Proposed acquisition of Apellis PharmaceuticalsM&A
Background
Biogen sought immediate commercial growth and broader exposure to complement-mediated immunology, nephrology, rare disease, and retinal disease.
Action taken
Biogen announced an agreement to acquire Apellis Pharmaceuticals, subject to customary closing conditions.
Aftermath
If completed, the transaction would add Empaveli and Syfovre, Apellis's commercial infrastructure, and additional capabilities relevant to Biogen's kidney-disease and immunology strategy.
Source
2025
Invest in Research Triangle Park manufacturingStrategy
Background
Biogen identified manufacturing scale, supply resilience, and support for multiple drug modalities as strategic priorities.
Action taken
The company announced a further $2 billion investment across its North Carolina manufacturing campuses.
Aftermath
The investment is intended to modernize facilities, support biologic and oligonucleotide production, and strengthen long-term supply capacity.
Planned manufacturing investment. $2 billion (Announced in 2025; investment program extending into subsequent years)
Source
2024
Acquire Human Immunology BiosciencesM&A
Background
Biogen sought to diversify beyond mature MS products and strengthen its presence in immunology and kidney disease.
Action taken
Biogen completed the acquisition of HI-Bio and obtained the felzartamab development program and related immunology capabilities.
Aftermath
The acquisition added a late-stage immunology and nephrology platform to Biogen's growth portfolio.
Source
2023
Advance Leqembi in Alzheimer's diseaseProduct launch
Background
Following the difficult Aduhelm experience, Biogen and Eisai advanced a second anti-amyloid antibody supported by a confirmatory clinical trial.
Action taken
Leqembi received accelerated approval and subsequently traditional FDA approval after confirmatory evidence supported clinical benefit.
Aftermath
Leqembi became the principal Alzheimer's product in the Biogen-Eisai collaboration and a major test of the commercial viability of disease-modifying Alzheimer's therapies.
Source
2021
Pursue accelerated approval and commercialization of AduhelmProduct launch
Background
Biogen and Eisai pursued regulatory approval for an anti-amyloid Alzheimer's medicine after clinical development produced conflicting efficacy findings but evidence of plaque reduction.
Action taken
The FDA granted accelerated approval based on the surrogate endpoint of amyloid-plaque reduction.
Aftermath
The decision produced intense regulatory and commercial controversy, restricted reimbursement, and contributed to the later discontinuation of the global Aduhelm program.
Source
2019
Acquire Nightstar TherapeuticsM&A
Background
Biogen sought to expand into gene therapy and rare inherited diseases.
Action taken
Biogen completed the acquisition of Nightstar Therapeutics and obtained its ophthalmology-focused gene-therapy platform.
Aftermath
The transaction broadened Biogen's development capabilities in gene therapy and rare disease, although individual programs remained subject to clinical and regulatory risk.
Source
2016
Launch Spinraza for spinal muscular atrophyProduct launch
Background
Biogen and Ionis developed an antisense medicine for SMA, a severe neuromuscular disease with limited treatment options.
Action taken
Following FDA approval, Biogen commercialized Spinraza as the first approved treatment for SMA.
Aftermath
Spinraza became a landmark product and established Biogen as a leading company in neuromuscular disease.
Source
2015
Rebrand Biogen Idec as BiogenStrategy
Background
The company concluded that the shorter Biogen name better represented its scientific heritage and its renewed emphasis on high-unmet-need diseases.
Action taken
Biogen Idec changed its corporate name to Biogen and introduced a new corporate identity.
Aftermath
The company returned to the name under which it had been founded while continuing as the legal successor to the Biogen-IDEC combination.
Source
2003
Merge with IDEC PharmaceuticalsM&A
Background
Biogen sought to combine its established neurology business with IDEC's antibody, oncology, and immunology capabilities.
Action taken
The companies completed a merger on November 12, 2003, creating Biogen Idec.
Aftermath
The combined company became a major biotechnology organization with businesses spanning neurology, oncology, immunology, and specialty medicines.
Source

Recent events

2026
Biogen announces proposed acquisition of Apellis Pharmaceuticals[10]Biogen and Apellis transaction announcementinvestors.biogen.com
M&A · strategy
Biogen announced an agreement to acquire Apellis Pharmaceuticals, subject to closing conditions, to add Empaveli and Syfovre and expand its presence in immunology, nephrology, rare disease, and retinal disease.
2025
Biogen announces planned new global headquarters in Cambridge[3]Biogen U.S. legacy and headquarters informationbiogen.com
strategy · Other
The company announced plans for a new Cambridge headquarters targeted for opening in 2028, coinciding with its fiftieth anniversary.
2025
Biogen announces $2 billion Research Triangle Park investment[17]North Carolina manufacturing investmentbiogen.com
strategy · Other
Biogen announced a further $2 billion investment to modernize and expand manufacturing capabilities across its North Carolina campuses and support multiple manufacturing modalities.
2024
Biogen completes acquisition of Human Immunology Biosciences[16]Human Immunology Biosciences acquisitioninvestors.biogen.com
M&A · strategy
Biogen acquired HI-Bio to strengthen its immunology and nephrology pipeline, including the investigational antibody felzartamab.
2023
FDA grants traditional approval to Leqembi[9]FDA Leqembi traditional approvalfda.gov
Product launch · Regulation
The FDA granted traditional approval to Leqembi, the Eisai and Biogen Alzheimer's disease therapy, after earlier accelerated approval based on amyloid reduction.
2023
FDA approves Qalsody for SOD1-ALS[15]Qalsody and Skyclarys are approvedfda.gov
Product launch · Regulation
The FDA approved Qalsody, an antisense oligonucleotide developed by Biogen, for adults with amyotrophic lateral sclerosis associated with a mutation in the SOD1 gene.
2023
FDA approves Skyclarys for Friedreich's ataxia[18]FDA批准Skyclarys用于弗里德赖希共济失调fda.gov
Product launch · Regulation
The FDA approved Skyclarys as the first treatment for Friedreich's ataxia, a rare inherited neurodegenerative disease.
2023
FDA approves Zurzuvae for postpartum depression[19]FDA批准Zurzuvae用于产后抑郁症fda.gov
Product launch · Regulation
The FDA approved Zurzuvae, developed by Sage Therapeutics and Biogen, as an oral treatment for postpartum depression.
2023
Biogen and Eisai receive FDA accelerated approval for Leqembi[20]渤健与卫材的Leqembi获FDA加速批准fda.gov
Product launch · Regulation
Leqembi received accelerated approval in the United States based on evidence that it reduced amyloid-beta plaques in patients with early Alzheimer's disease.
2022
Biogen and Eisai discontinue global Aduhelm clinical program[21]渤健与卫材终止Aduhelm全球临床项目investors.biogen.com
Product generation · Other
Biogen and Eisai announced the discontinuation of the confirmatory clinical trial and commercial development program for Aduhelm after market access and commercial conditions remained difficult.

Showing the 10 most recent.

Sources35 sources

Cite this profile: Cite the canonical profile. /brand-wiki/biogen · Editorial policy · How profiles are compiled